Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $8.20, for a total transaction of $41,000.00. Following the completion of the sale, the chief technology officer owned 177,171 shares of the company’s stock, valued at approximately $1,452,802.20. This trade represents a 2.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.80, for a total transaction of $44,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.60, for a total transaction of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.95, for a total transaction of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Down 1.4%

Shares of SOPH stock traded down $0.12 during trading hours on Wednesday, hitting $8.53. 232,020 shares of the company were exchanged, compared to its average volume of 241,759. The stock has a market capitalization of $715.58 million, a price-to-earnings ratio of -7.42 and a beta of 0.96. SOPHiA GENETICS SA has a one year low of $3.10 and a one year high of $8.85. The business’s 50-day simple moving average is $6.33 and its two-hundred day simple moving average is $5.37. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. Sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS during the 4th quarter worth $49,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS during the third quarter valued at $49,000. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS during the first quarter valued at $50,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter worth about $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter worth about $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research increased their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, HC Wainwright increased their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.